Herceptin
E46088
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
Aliases (4)
- trastuzumab ×2
- trastuzumab-dkst ×1
- trastuzumab-pkrb ×1
- trastuzumab-qyyp ×1
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
→
biologic drug → monoclonal antibody → targeted therapy → |
| antibodyIsotype | IgG1 → |
| antibodyTarget | ERBB2 → |
| bindsTo |
ERBB2
→
surface form: "human epidermal growth factor receptor 2"
|
| boxedWarningFor |
cardiac toxicity
→
embryo-fetal toxicity → |
| FDAApprovalYear | 1998 → |
| hasATCCode | L01FD01 → |
| hasBiosimilar |
Herceptin
→
surface form: "trastuzumab-dkst"
trastuzumab-dttb → Herceptin →
surface form: "trastuzumab-pkrb"
Herceptin →
surface form: "trastuzumab-qyyp"
|
| hasCASNumber | 180288-69-1 → |
| hasDrugClass |
HER2 inhibitor
→
antibody-based therapy → |
| hasGenericName |
Herceptin
→
surface form: "trastuzumab"
|
| hasMolecularType | humanized monoclonal antibody → |
| hasUNII | P188ANX8CK → |
| isAdministeredAs | weight-based dosing → |
| isContraindicatedWith | severe hypersensitivity to trastuzumab → |
| isIndicatedAs |
adjuvant therapy
→
neoadjuvant therapy → |
| isIndicatedInCombinationWith |
carboplatin
→
docetaxel → paclitaxel → pertuzumab → |
| isListedOn | World Health Organization Model List of Essential Medicines → |
| isMarketedBy | Roche → |
| isProducedBy | Genentech → |
| isUsedFor |
HER2-positive breast cancer
→
HER2-positive gastric cancer → HER2-positive gastroesophageal junction adenocarcinoma → early-stage HER2-positive breast cancer → metastatic HER2-positive breast cancer → |
| mechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
→
inhibits HER2-mediated signaling pathways → prevents HER2 receptor dimerization → |
| requiresTestingFor |
HER2 gene amplification
→
HER2 overexpression → |
| routeOfAdministration | intravenous infusion → |
| seriousAdverseEffect |
cardiomyopathy
→
congestive heart failure → infusion-related reactions → pulmonary toxicity → |
| targets | HER2 receptor → |
| wasApprovedBy |
Food and Drug Administration
→
surface form: "U.S. Food and Drug Administration"
|
Referenced by (7)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form: "trastuzumab-dkst"
this entity surface form: "trastuzumab-pkrb"
this entity surface form: "trastuzumab-qyyp"
this entity surface form: "trastuzumab"
this entity surface form: "trastuzumab"